Beyond the Clinic: Iatrogenix Tackles Neurology's Adherence Gap

NEW YORK, NY – February 09, 2026 – A new clinician-founded company, Iatrogenix™, launched today with a model designed to address a critical, often overlooked vulnerability in modern healthcare: the period between doctor's appointments. For patients with chronic neurological conditions like migraine, this "continuity gap" can be a lonely and confusing time where even the most effective treatments are abandoned, not due to clinical failure, but because the daily reality of living with them becomes unsustainable.

The Silent Crisis of Non-Adherence

The journey of a patient with a chronic neurological disorder is frequently punctuated by long intervals between specialist visits. A prescription is written, a treatment plan is set, but what happens in the weeks and months that follow is often a silent struggle. Research confirms this is a systemic issue, not one of patient noncompliance.

Data on chronic conditions reveals a stark pattern of "non-persistence." In multiple sclerosis, for example, studies have shown that within two years of starting therapy, as few as 30% of patients may still be following treatment recommendations. The reasons are multifaceted and deeply human. Forgetfulness, often exacerbated by the cognitive burden of the condition itself, is a common factor. The onset of side effects, the high financial cost of therapies, and a lack of perceived immediate benefit also lead patients to quietly stop their medications.

This disengagement has measurable consequences. For patients, it can mean more frequent relapses, increased hospitalizations, and a decline in overall health. For clinicians, it creates a frustrating cycle of incomplete trials; they may interpret a treatment as having failed when, in reality, it was never given a fair chance to work. This erodes the therapeutic relationship and leads to unnecessary cycling through different interventions, straining a healthcare system already burdened by long wait times and limited resources.

The Iatrogenix press release identifies this as a failure of infrastructure rather than a clinical or patient error. "What appears to be therapeutic failure often reflects insufficient infrastructure surrounding treatment," the company states. This perspective reframes the problem, shifting focus from blaming the patient to supporting their lived experience.

A Companion Layer for Chronic Care

In response to this gap, Iatrogenix has introduced its Companion Support Model, debuting with programs for migraine and mental clarity. The company is careful to define its role: it does not diagnose, treat, or replace medical care. Instead, it positions itself as a complementary "companion layer" designed to provide education, structure, and support to help patients stay engaged with their prescribed care plans.

The core of the model is a 12-week "follow-along course platform" that is bundled with the purchase of one of their neuro-nutritional formulas, such as MigraMute™ for migraine support or TurBalance™ for mental clarity. These courses aim to give patients a framework for understanding their physiological experiences between appointments, reducing the uncertainty that often drives disengagement.

The formulas themselves are a key part of the support structure. MigraMute™, for instance, contains a blend of clinically studied nutrients like CoQ10, Magnesium, and Riboflavin. The company notes it deliberately excludes common herbal ingredients like butterbur and feverfew, citing concerns over variable safety and consistency, opting instead for nutrients with established long-term safety profiles. This approach underscores their focus on providing a reliable, supportive tool for individuals who are already using prescription therapies, awaiting evaluation, or exploring non-pharmacologic strategies.

The company's name itself, Iatrogenix™, is a re-framing of a medical concept. While "iatrogenic" traditionally refers to harm caused by medical intervention, the company uses it to acknowledge that all effective treatments alter physiology by design. Their model is built on the idea that patients benefit from structured support as they navigate these intended physiological shifts.

A Clinician-Informed Perspective

The scientific credibility of the Iatrogenix model is bolstered by its scientific oversight from Dr. Nick Tzikas, a board-certified physician and Assistant Professor of Clinical Neurology at Yale School of Medicine. A fellowship-trained headache and facial pain specialist, Dr. Tzikas co-directs the Head and Facial Pain fellowship program at Yale.

His involvement stems from a direct understanding of the clinical challenge. In the company's launch materials, he notes that "patients often abandon clinically appropriate treatments because they lack continuity of support between visits and are expected to navigate complex physiological experiences without context for months at a time."

The company's origin story is also rooted in clinical experience. It was founded by Pepie Tzikas, an occupational therapist and Dr. Tzikas's wife, whose shared personal and professional experiences with migraine served as the catalyst for developing the support model. This blend of professional expertise and personal insight highlights a deep understanding of the functional and emotional burdens that accompany chronic neurological conditions.

Redefining Support in a Digital Age

Iatrogenix enters a bustling health technology market filled with digital therapeutics (DTx), patient engagement platforms, and condition-specific mobile apps, all vying to improve patient outcomes. Companies like Omada Health and Livongo have pioneered digital support for chronic conditions like diabetes, while a proliferation of apps offers symptom tracking and community for those with MS and migraine.

However, Iatrogenix's model differentiates itself by bundling a physical product—the neuro-nutritional formula—with a structured educational program. This direct-to-consumer approach, with products priced at $75 including the 12-week course, carves out a unique niche. It is less a pure-play digital health solution and more of a hybrid that combines nutritional science with behavioral scaffolding. It aims not to replace the doctor, but to make the time between seeing the doctor more productive and less isolating.

As treatment complexity increases and the healthcare system struggles with capacity, the need for such supportive infrastructure is becoming more apparent. The success of advanced medical interventions no longer depends solely on the efficacy demonstrated in a controlled clinical trial. It hinges on a patient's ability to sustain engagement with that intervention in the messy, unpredictable context of daily life. By focusing on this critical interval, Iatrogenix is betting that the future of effective chronic care lies not just in new prescriptions, but in building the support systems that help patients see them through.